Sue Gail Eckhardt
Known title: DirectorCIK: 0001823769
Associated companies
Transaction History
| EXEL | ▼ Sell | Open Market | 9,812 | $492K | 6/1/2026 | View on chart |
| EXEL | ▲ Buy | Grant | 8,367 | $0 | 5/27/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 3,856 | $169K | 2/13/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 18,834 | $805K | 6/2/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 4 | $175 | 6/2/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 9,812 | $0 | 5/29/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 7,712 | $179K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 7,712 | $270K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 3,856 | $135K | 2/14/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 18,838 | $0 | 5/31/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 15,424 | $0 | 1/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue
Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.